BioSuperior Technology is developing innovative therapeutics for the treatment of serious lung disease in both adults and preterm babies. Our lead candidate repairs lung tissue that has been damaged by Acute Respiratory Distress Syndrome (ARDS) due to due viral infection or other pathogens. Our compound has been shown to significantly increase survival in animal models infected with Pseudomonas aeruginosa. We believe that by preventing and repairing lung damage we will not only increase survival, but significantly reduce post-hospitalization health issues. In a typical year, 200,000 U.S. patients develop ARDS and 30 to 40% of them die. The cost to the US healthcare system is over $50B per year. In 2020, the number of ARDS-related deaths is expected to skyrocket to 300,000.
Our team is made up of Drs. Lucia Mokres, Ehud Goldin, Hong Zhao, and myself. We are pharmaceutical scientists with complementary expertise and an average of 25 years of experience. We have made significant contributions to the research and development of many therapeutics, including Tysabri, Macugen, and Growth Hormone. In addition, our Advisors are top tier scientists in their fields. They include: Professors Jahar Bhattacharya (Columbia U), Matt Baldwin (Columbia U), Dr. John Patton (founder of Nektar), Dr. Jeffrey Whitsett (Cincinatti Childrens’ Hospital), and Dr. John Mott (VP Cytovance).
To date, we have received grants from the NSF I-Corps and March of Dimes. We are raising $750K to manufacture our lead compound in a stable, mammalian cell line and confirm that it can be used to effectively treat Sars-CoV-2 infected individuals. We expect to file an Investigational New Drug Application in 2021 and start first-in-human clinical trials in early 2022.